WO2009052426A3 - Oncolytic virus - Google Patents

Oncolytic virus Download PDF

Info

Publication number
WO2009052426A3
WO2009052426A3 PCT/US2008/080367 US2008080367W WO2009052426A3 WO 2009052426 A3 WO2009052426 A3 WO 2009052426A3 US 2008080367 W US2008080367 W US 2008080367W WO 2009052426 A3 WO2009052426 A3 WO 2009052426A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncolytic virus
therapeutic
regrowth
armed
encodes
Prior art date
Application number
PCT/US2008/080367
Other languages
French (fr)
Other versions
WO2009052426A2 (en
Inventor
Balveen Kaur
Antonio Chiocca
Yoshinaga Saeki
Original Assignee
Univ Ohio State
Balveen Kaur
Antonio Chiocca
Yoshinaga Saeki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State, Balveen Kaur, Antonio Chiocca, Yoshinaga Saeki filed Critical Univ Ohio State
Publication of WO2009052426A2 publication Critical patent/WO2009052426A2/en
Publication of WO2009052426A3 publication Critical patent/WO2009052426A3/en
Priority to US12/697,891 priority Critical patent/US8450106B2/en
Priority to US13/903,695 priority patent/US20130316447A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Malignant tumors that are intrinsically resistant to conventional therapies are significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as a tumor cells. In various embodiments presented herein, the oncolytic virus is armed or encodes a therapeutic polypeptide. In at least one embodiment, a recombinant oncolytic virus has been generated that can specifically replicate in cancer cells leading to their destruction and at the same time secrete robust amounts of an angiostatic factor to inhibit the regrowth of residual disease. Compositions and methods disclosed herein have broad therapeutic applicability.
PCT/US2008/080367 2007-10-17 2008-10-17 Oncolytic virus WO2009052426A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/697,891 US8450106B2 (en) 2007-10-17 2010-02-01 Oncolytic virus
US13/903,695 US20130316447A1 (en) 2007-10-17 2013-05-28 Oncolytic virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98066407P 2007-10-17 2007-10-17
US60/980,664 2007-10-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/697,891 Continuation US8450106B2 (en) 2007-10-17 2010-02-01 Oncolytic virus

Publications (2)

Publication Number Publication Date
WO2009052426A2 WO2009052426A2 (en) 2009-04-23
WO2009052426A3 true WO2009052426A3 (en) 2009-07-30

Family

ID=40568089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/080367 WO2009052426A2 (en) 2007-10-17 2008-10-17 Oncolytic virus

Country Status (1)

Country Link
WO (1) WO2009052426A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20060099224A1 (en) * 2002-08-12 2006-05-11 David Kirn Methods and compositions concerning poxviruses and cancer
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20060099224A1 (en) * 2002-08-12 2006-05-11 David Kirn Methods and compositions concerning poxviruses and cancer
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. YAMAMOTO ET AL.: "Imaging innediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.", GENE THERAPY., vol. 13, 2006, pages 1731 - 1736 *

Also Published As

Publication number Publication date
WO2009052426A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
EP1767642A4 (en) Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
WO2018209194A3 (en) Newcastle disease viruses and uses thereof
WO2006103562A3 (en) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
WO2006031996A3 (en) Targeting viruses using a modified sindbis glycoprotein
WO2005086922A3 (en) Oncolytic adenovirus armed with therapeutic genes
EP3699270A4 (en) Isolated recombinant oncolytic adenovirus, pharmaceutical composition, and application of isolated recombinant oncolytic adenovirus in medication for treatment of tumor and/or cancer
EA201991622A1 (en) COMPLEX THERAPY FOR TREATMENT OF CANCER
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
WO2007098611A8 (en) Compositions for treatment of cancer
EA201200560A1 (en) SPECIFIC THERAPY USING INTEGRINE LIGANDS FOR CANCER TREATMENT
WO2007055941A3 (en) Histone deacetylase inhibitors with aryl-pyrazolyl motifs
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
WO2011053991A3 (en) Vault complexes for cytokine delivery
WO2007112316A3 (en) Mycobacterial immunotherapy for cancer treatment
EA200900912A1 (en) SPECIFIC THERAPY AND MEDICATION ON THE BASIS OF INTEGRINE LIGANDS FOR TREATMENT OF CANCER
MX2023011105A (en) Optimized oncolytic viruses and uses thereof.
MX2009005293A (en) Novel antiproliferation antibodies.
MX2017011600A (en) Antibody therapeutics that bind psma.
EA201101651A1 (en) CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT
MX2019008105A (en) Virus.
WO2015191568A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2020018996A3 (en) Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
EP4371584A3 (en) Scaffolds to treat solid tumor cells and escape variants
EP3858369A4 (en) Cancer therapy where oncolytic vaccinia virus and immune checkpoint inhibitor are used in combination, and pharmaceutical composition and combination drug used therein
WO2020022898A3 (en) Off-the-shelf cancer vaccines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08839446

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08839446

Country of ref document: EP

Kind code of ref document: A2